HLS management has successfully executed over $8 billion (CAD) of transactions in the pharmaceutical space, with a focus on CNS products, and managed a rich portfolio of promoted and legacy therapies.

We bring to the table substantial capital resources, a thoughtful strategy, a highly sophisticated team with direct experience and a track record of success.

In August 2015, HLS completed the acquisition of the U.S. and Canadian rights to CLOZARIL^® (clozapine), a pharmaceutical product used in the treatment of schizophrenia. The financing for the acquisition was completed with the participation of leading healthcare investors. In September 2017, HLS Licensed the rights to register, commercialize and distribute Vascepa^® in Canada and in November 2017, HLS licensed the rights to register, commercialize and distribute Trinomia^® in Canada. In February 2019, HLS announced that it has licensed the rights to and filed the Athelas One Point-of-Care diagnostic device that it will introduce in Canada under the CSAN^® Pronto^TM name and in April, HLS Licensed the rights to register, commercialize and distribute Perseris^® a long acting anti-psychotic used in the first line treatment of schizophrenia.

HLS Therapeutics is looking for additional opportunities in the pharma market to build its commercial portfolio.

• Type of Acquisition/Licensing: Pre-Commercial or Commercial Stage Therapies as well as Mature/Legacy Assets
• Territory Global: Focus on North America (U.S. and Canada)
• Therapeutic Area: CNS, Cardiovascular, and selected Disease States where focus and dedication can trump scale

If you would like to present HLS with any acquisition opportunities, please contact:

Pauline Dapena-Cherry
Director Corporate & Business Development
Email: p.dapenacherry@hlstherapeutics.com
Phone: 484-232-3400 ext. 107